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Introduction
Human T cell lymphotropic type 1
(HTLV-1) was the first human retrovirus
discovered and has been associated mainly
with two illnesses [1], an inflammatory
disease named HTLV-1-associated mye-
lopathy/tropical spastic paraparesis
(HAM/TSP), and a neoplastic condition
called adult T cell leukemia/lymphoma
(ATL) [2]. Although this virus has world-
wide distribution, Japan, Africa, the
Caribbean basin, and South America are
considered to be endemic areas [3]. It has
been estimated that 10–20 million people
are infected with this virus [4], but the
majority are asymptomatic and probably
not aware of their serological status. There
is no accurate number of HAM/TSP or
ATL cases since these diseases are not
considered reportable by the World Health
Organization (WHO), although Japan re-
ports approximately 800 cases of ATL
yearly [5]. In 1985, Roman et al. used the
term tropical spastic paraparesis (TSP) for
the first time, modifying the term ‘‘tropical
spastic paraplegia’’ as used in South India
in 1969, because only a few cases were
completely paraplegic [6]. In the same year,
it was found that almost 60% of patients
with TSP were also positive for HTLV-1
compared with 4% of the controls, which
suggested, for the first time, the neurotro-
pism of human retroviruses [7]. In 1986,
Osame et al. coined the term HTLV-1-
associated myelopathy (HAM) [8]. In 1988,
the WHO recommended ‘‘that the disease
be known by the acronym HAM/TSP for
the time being.’’ Thus, it seems that in
endemic areas, about 60% of tropical
spastic paraparesis cases are identified as
HAM/TSP [7]. The rest are myelopathies
probably caused by nutrition problems,
intoxication, and unknown causes [6,9].
HAM/TSP has an estimated incidence
ranging from 0.25% to 1% after 30–40
years of incubation [9]. The onset of
disease is 40 years of age, with predomi-
nance in women [10]. Several factors have
been ascribed as potentials for clinical
outcome, such as high HTLV-1 proviral
load, genetic background, routes of trans-
mission (i.e., breastfeeding or transfusion),
and high antibody titers [11].
Despite the publication of several re-
views regarding the pathogenesis or mo-
lecular biology of HTLV-1 [12,13], few
studies have addressed treatment for the
diseases caused by this virus. Thus, this
article will focus on the reason why HAM/
TSP should be considered a neglected
tropical disease.
To illustrate our viewpoint, we present
one case of HAM/TSP in which several
important issues are raised as singularities
of the problem. A 29-year-old black
woman born in Bahia in northeast Brazil
has been living in Sa˜o Paulo city for several
years. When she was 20, she began
complaining of lumbar pain and parestesis,
initially in one leg and then in both, in
addition to miccional urgency and consti-
pation. After 3 years of illness and several
visits to doctors, including basic and
intermediate complexity level services, she
was referred to our service as a suspected
case of HTLV-1 disease. The diagnosis of
HAM/TSP was confirmed. The patient
was using a wheelchair most of the time.
Pulse therapy with methylprednisolone was
administered three to four times per year,
with programmed hospitalization for at
least 5 days. Her husband abandoned her,
and she lives with her two children in a
small one-bedroom house in an area
difficult to reach by car. Her only income
is the government minimum wage
(US$250.00/month), and she is unable to
attend a facility for physical therapy. She
depends on her friends or relatives to bring
her to the clinic appointments.
There Is No Specific
International Classification of
Disease for this Condition
The neurological disease TSP/HAM has
no International Classification of Disease
(ICD-10) code. In our clinical practice, we
use the G04.1 code to designate this
condition. This code means Tropical
Spastic Paraplegia. In fact, many of our
patients, when they need social security
assistance, must present one report of ICD-
10 by an attending physician. For this
reason, we provide an ICD-10 closest to the
clinical features of HAM/TSP. The crea-
tion of an ICD-10 code specifically for
HAM/TSP would solve this problem and
avoid any complications for physicians
when they provide this report. Further-
more, this specific and more accurate code
would also allow for the surveillance of the
number of cases in the population, if this
condition becomes an obligatory reportable
condition by WHO in the future.
Neurologists and Orthopedists,
as Well as Other Health
Professionals, Have Little or No
Knowledge of This Condition,
and This May Have Great Impact
on the Accuracy of Diagnosis
We believe that the main reason for the
low level of knowledge about HAM/TSP
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is the difficulty of diagnosis. The current
guideline was recently updated by experts
from several parts of the world [14]. It is
possible that recommendations are too
restrictive and specific. Easier recommen-
dations should be implemented to facili-
tate diagnosis and reporting by non-HTLV
experts in the clinical setting, especially in
developing countries.
Based on our clinical experience here in
Brazil, we suggest that HAM/TSP be
characterized as a chronic, slowly progres-
sive, spastic paraparesis with bladder
disturbances, absent or mild sensory loss
and low back pain, and positivity for
HTLV-1 antibodies in serum and cere-
brospinal fluid [7]. The HAM/TSP
diagnosis must exclude spinal cord com-
pression, hypovitaminosis of B complex,
hypo- or hyperthyroidism, or other causes
of pyramidal syndrome, and impotence in
men is a common picture. Overall, one-
fifth of patients may experience a rapid
progression, with severe disability two
years after the onset of symptoms [15].
Because of the symptoms and signs of
HAM/TSP, most patients are referred to
or are seen for the first time by neurologists,
orthopedists, urologists, or other health
professionals involved in the rehabilitation
process (physical therapists, for example).
These professionals may have little knowl-
edge of HAM/TSP or HTLV-1 infection,
and a lack of information regarding this
condition may delay the diagnosis. In fact,
the mean time for correct diagnosis of
HAM/TSP patients in our clinic was 7
years. Carod-Artal et al. found that 17% of
the patients who were followed up in the
most important rehabilitation hospital in
central Brazil (in Brasilia, Brazil’s capital)
had HAM/TSP diagnosis, with a mean
time of diagnosis of 11 years [16]. It is an
important issue since early recognition of
the disease may improve the prognosis and
the response to treatment [17].
This problem could be addressed by
improving the teaching of HTLV during
undergraduate training and medical resi-
dency in places where HTLV-1 is endemic.
In addition, lectures and/or case discussions
during national meetings of these specialties
could provide better information for these
professionals. Furthermore, guidelines such
as those released by the US Centers for
Disease Control as well as Brazilian HTLV
guidelines should be updated and be
universally accepted [18,19].
One good strategy for providing better
information to the public as well as to
health care providers is using the Internet.
A Web site was created in 2003 with
general information regarding HTLV
infection and the associated diseases, as
well as information for the general public
in non-technical terms to address the most
frequently asked questions (http://www.
htlv.com.br). This Web site has informa-
tion in three languages, Portuguese, Span-
ish, and English, and for the first year had
financial support from the Ministry of
Health of Brazil. There is considerable
interest in this site, with an average of
5,000 visits per month.
No Useful Treatments Are
Available
Despite the 24 years that have passed
since the first HAM/TSP cases were
described in Martinique, no successful
treatment is available to treat HAM/TSP
patients (reviewed by [20]). Most treat-
ments have been directed at reducing
inflammation in the affected tissues. The
use of interferon-a, oral prednisolone,
intrathecal hydrocortisone, plasmapheresis,
vitamin C, and antiretroviral drugs has
been reported. There are some reports of
transient benefits of immunotherapy, pen-
toxyfiline, danazol, milk drinks containing
Lactobacillus casei, and more recently, val-
proic acid [21]. Even though corticoste-
roids are the most widely used therapy for
TSP/HAM, few clinical trials with cortico-
steroids have been published recently. In
our experience, only 25% of patients
showed neurological improvement with
the use of corticosteroids, with physical
therapy and anti-spastic drugs as adjunctive
treatment [22]. Thus, larger multicenter
randomized clinical trials to assess the use
of corticosteroids and other potentially
useful immune-based therapies for HAM/
TSP treatment are urgently necessary.
Finally, recognition of HAM/TSP as a
neglected disease would provide more
focus on this condition, perhaps increasing
the number of researchers in this field,
which could lead to the development of
better treatment options for patients and
also avoid the confusion between HTLV-1
and HIV-1 (even at a professional level)
without adding further stigma on these
individuals.
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